Navigation Links
Accuri Cytometers Completes $13 Million Series C Financing
Date:7/8/2008

Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes venture capital investments in early- and expansion-stage business services and healthcare/life sciences companies. Baird Venture Partners leverages its in-depth sector knowledge, experienced investment team and network of relationships to serve as a value-added partner for its portfolio companies. With a global team of 80 professionals in nine offices across the United States, Europe and Asia, Baird Private Equity and its affiliates have raised and managed approximately $2.4 billion in capital and invested in over 220 companies since the 1980s. For more information, please visit http://www.bairdventurepartners.com and http://www.bairdprivateequity.com.

About Arboretum Ventures

Arboretum Ventures is an early-stage venture capital firm specializing in the healthcare sector. Arboretum Ventures focuses primarily on investments in medical technology and healthcare services. Arboretum invests throughout the United States, with a special interest in the Midwest region. Founded in 2002 with headquarters in Ann Arbor, Mich., Arboretum Ventures currently manages $85 million in capital. For more information, please visit http://www.arboretumvc.com.

For additional information, contact:

Accuri Cytometers Media

Jennifer A. Baird GendeLLindheim BioCom Partners

Chief Executive Officer Barbara Lindheim

(734) 994-8000 (212) 918-4650


'/>"/>
SOURCE Accuri Cytometers Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
2. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
3. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
4. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
5. Boston Scientific Completes Acquisition of CryoCor
6. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
7. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
8. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
9. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
10. China-Biotics, Inc. Completes Foundation for Its New Plant
11. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... 2014 Fast, semi-automatic creation ... in documents ChemAxon , a ... services for life science research, launches ChemCurator, an ... structures from documents. Markush structures are ... generating and understanding Markush structures is a difficult ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... convertible notes, and extended the maturity to 2011 on an additional $23.25 ... ... Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq and MTAX: CTIC) today announced ... "New Notes") due 2011 and 5,459,574 shares of its common stock,no par ...
... Biosciences,Inc. (Nasdaq: NBIX ) announced today that the ... Administration (FDA) indicating,that the New Drug Application (NDA) for ... of insomnia is approvable pending additional clinical and,preclinical data., ... action letter from the FDA,stating that indiplon 5 mg ...
... Company Mails Letter to Shareholders, MONTVALE, N.J., ... today announced that Glass Lewis & Co., one ... that Datascope,shareholders re-elect the Board,s nominees -- James ... Company,s Annual Meeting of Shareholders on,Thursday, December 20, ...
Cached Biology Technology:Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 2Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 4Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 5Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 6Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 7
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... Research on Aging (Novato, CA) and Biotica Technology Ltd. ... polyketides in diseases of aging. Building on observations that ... Kennedy; Nature 2009), the collaborators will evaluate ... of age-related disease models to identify novel therapeutics. ...
... no crime. Consider that some strains of algae ... the less harmful varieties suck oxygen out of water, ... Recent algal blooms in the Great Lakes, for instance, ... Andr Hudson and colleagues have figured out how to ...
... Cornell University researchers may have solved a 100-year puzzle: ... that therapies to treat Alzheimer,s disease, multiple sclerosis and cancers ... Journal of Neuroscience , Sept. 14, 2011.) , The ... can modulate the entry of large molecules into the brain. ...
Cached Biology News:Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan 2Outsmarting algae -- RIT scientist finds the turn-off switch 2Breaching the blood-brain barrier 2
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: